Evidence map›Paper›PMID 37063842›Full record

ArticleFrontiers in immunology2023

A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells.

Vera S Donnenberg, James D Luketich, Ibrahim Sultan, John Lister, David L Bartlett, Sohini Ghosh, Albert D Donnenberg

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Vera S DonnenbergDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
James D LuketichDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
Ibrahim SultanDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
John ListerDepartment of Medicine, Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States.
David L BartlettDrexel University College of Medicine, Philadelphia, PA, United States.
Sohini GhoshDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Allegheny Health Network, Pittsburgh, PA, United States.
Albert D DonnenbergUniversity of Pittsburgh Medical Center (UPMC) Hillman Cancer Centers, Pittsburgh, PA, United States.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0M
Three-dimensional organoid models to study breast cancer progressionR37CA232209 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SANT, SHILPA · 2018 to 2024
$3.0M
NCI NIH HHS P30 CA047904NCI NIH HHS R37 CA232209
6 · The paper itself

Abstract

Introduction: Treatment options for patients with malignant pleural effusions (MPE) are limited due, at least in part, to the unique environment of the pleural space, which drives an aggressive tumor state and governs the behavior of infiltrating immune cells. Modulation of the pleural environment may be a necessary step toward the development of effective treatments. We examine immune checkpoint molecule (ICM) expression on pleural T cells, the secretomes of pleural fluid, pleural infiltrating T cells (PIT), and ability to activate PIT Methods: ICM expression was determined on freshly drained and Results: ICM expression was low on freshy isolated PIT; regulatory T cells (T-reg) were not detectable by GeoMx. Discussion: Despite the negative environment, immune effector cells are plentiful, persist in MPE in a quiescent state, and are easily activated and expanded in culture. Low expression of ICM on native PIT may explain reported lack of responsiveness to immune checkpoint blockade. The potent cytotoxic activity of activated PIT and a proof-of-concept clinical scale GMP-expansion experiment support their promise as a cellular therapeutic. We expect that a successful approach will require combining cellular therapy with pleural conditioning using immune checkpoint blockers together with inhibitors of upstream master cytokines such as the IL-6/IL-6R axis.

Indexed as

Epithelial-Mesenchymal TransitionPleural Effusion, MalignantCytokinesHumansInterleukin-6ProteomicsT-Lymphocytes, RegulatoryCytokinesInterleukin-6adoptive cellular therapyimmune checkpoint moleculesimmunotherapymalignant pleural effusionNanostring GeoMxpleural T cellssecretomics

Identifiers

PMID37063842
PMCPMC10097923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.